Article Details

Short-course neoadjuvant immunotherapy confers high response rates in colon cancer subset

Retrieved on: 2022-09-15 15:28:01

Tags for this article:

Click the tags to see associated articles and topics

Short-course neoadjuvant immunotherapy confers high response rates in colon cancer subset. View article details on hiswai:

Excerpt

... Roche/Genentech, Taiho Oncology and Xenthera, as well as grants to his institution from Bristol Myers Squibb, Genentech and Verastem Oncology.

Article found on: www.healio.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up